 | |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H30O2 |
| Molar mass | 314.469 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Abnormal cannabidiol (Abn-CBD) is a syntheticregioisomer ofcannabidiol, which unlike most other cannabinoids producesvasodilator effects, lowersblood pressure, and inducescell migration,cell proliferation andmitogen-activated protein kinase activation inmicroglia, but without producing anypsychoactive orsedative effects.[1][2] Abn-CBD can be found as an impurity in syntheticcannabidiol.[3]
It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from theCB1 andCB2 receptors,[2][4] which responds to abnormal cannabidiol,O-1602, and theendogenous ligands:anandamide (AEA),N-arachidonoylglycine (NAGly) andN-arachidonoyl-L-serine.[2][5][6][7] Multiple lines of evidence support the proposed identification of this novel target inmicroglia as the previouslyorphan receptorGPR18.[2] Another possible target of abnormal cannabidiol isGPR55, which has also received much attention as a putative cannabinoid receptor,[8][9] although a growing body of evidence points tolysophosphatidylinositol (LPI) as theendogenous ligand for GPR55.[10][11] Further research suggests there are yet more additional cannabinoid receptors.[12][13][14][15]
Research of the effects on abnormal cannabidiol in mice has indicated that atypical cannabinoids have therapeutic potential in a variety of inflammatory conditions, including those of the gastrointestinal tract. After inducingcolitis by means oftrinitrobenzene sulfonic acid, wound healing of bothhuman umbilical vein endothelial andepithelial cells was enhanced by the Abn-CBD.[16]
